帕博利珠单抗联合铂类化疗在NSCLC稳定性脑转移患者中的疗效:KEYNOTE-021、-189和-407汇总分析
该探索性分析汇总KEYNOTE-021 G队列、KEYNOTE-189和KEYNOTE-407三项研究,比较一线帕博利珠单抗联合铂类化疗与单纯化疗在晚期NSCLC伴或不伴基线脑转移患者中的疗效。共纳入1298例患者,其中171例有脑转移。结果显示,无论有无脑转移,联合治疗均改善OS和PFS,且安全性可控。
要点
- 伴脑转移患者中,帕博利珠单抗联合化疗较单纯化疗延长中位OS(18.8 vs 7.6个月)和PFS(6.9 vs 4.1个月)。
- 伴与不伴脑转移患者的OS HR分别为0.48和0.63,PFS HR分别为0.44和0.55,获益趋势一致。
- 联合治疗组治疗相关不良事件发生率在伴脑转移患者中为88.2% vs 82.8%,不伴脑转移患者中为94.5% vs 90.6%。
核心结论
- 无论有无脑转移,帕博利珠单抗联合铂类组织学特异性化疗较单纯化疗改善临床结局,包括PD-L1 TPS<1%亚组,且安全性可控。
研究设计与样本
- 探索性回顾性汇总分析,纳入KEYNOTE-021 G队列(非鳞)、KEYNOTE-189(非鳞)和KEYNOTE-407(鳞)中晚期NSCLC患者,共1298例,其中171例有基线脑转移。
- 患者接受铂类双药化疗联合或不联合帕博利珠单抗200 mg每3周共35个周期。
主要发现
- 伴脑转移患者中,联合治疗组中位OS为18.8个月,单纯化疗组为7.6个月;中位PFS分别为6.9个月和4.1个月。
- 伴与不伴脑转移患者的OS HR分别为0.48(95%CI 0.32-0.70)和0.63(95%CI 0.53-0.75),PFS HR分别为0.44(95%CI 0.31-0.62)和0.55(95%CI 0.48-0.63)。
- 无论脑转移状态,联合治疗组客观缓解率更高且缓解持续时间更长。
关键数值与推荐
- 脑转移患者需既往治疗稳定至少2周(KEYNOTE-021 G队列≥4周),无新发或增大脑转移证据,且给药前至少3天未使用类固醇。
- 已知未治疗的无症状脑转移患者需定期脑 imaging。
临床怎么用
- 帕博利珠单抗联合铂类化疗可作为晚期NSCLC初治患者的标准治疗选择,包括稳定性脑转移患者。
局限性
- 为探索性回顾性分析,非预设主要终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This exploratory analysis retrospectively evaluated outcomes in patients with advanced NSCLC to determine whether baseline brain metastases influenced the efficacy of first-line pembrolizumab plus chemotherapy versus chemotherapy alone. METHODS: We pooled data for patients with advanced NSCLC in KEYNOTE-021 cohort G (nonsquamous), KEYNOTE-189 (nonsquamous), and KEYNOTE-407 (squamous). Patients were assigned to platinum-doublet chemotherapy with or without the addition of 35 cycles of pembrolizumab 200 mg every 3 weeks. All studies permitted enrollment of patients with previously treated or untreated (KEYNOTE-189 and KEYNOTE-407 only) stable brain metastases. Patients with previously treated brain metastases were clinically stable for 2 or more weeks (≥4 wk in KEYNOTE-021 cohort G), had no evidence of new or enlarging brain metastases, and had no steroid use at least 3 days before dosing. Patients with known untreated asymptomatic brain metastases required regular imaging of the brain. RESULTS: A total of 1298 patients were included, 171 with and 1127 without baseline brain metastases. Median (range) durations of follow-up at data cutoff were 10.9 (0.1‒35.1) and 11.0 (0.1‒34.9) months, respectively. Hazard ratios (pembrolizumab + chemotherapy/chemotherapy) were similar for patients with and without brain metastases for overall survival (0.48 [95% confidence interval (CI): 0.32‒0.70] and 0.63 [95% CI: 0.53‒0.75], respectively) and progression-free survival (0.44 [95% CI: 0.31‒0.62] and 0.55 [95% CI: 0.48‒0.63], respectively). In patients with brain metastases, median overall survival was 18.8 months with pembrolizumab plus chemotherapy and 7.6 months with chemotherapy, and median progression-free survival was 6.9 months and 4.1 months, respectively. Objective response rates were higher and duration of response longer with pembrolizumab plus chemotherapy versus chemotherapy regardless of brain metastasis status. Incidences of treatment-related adverse events with pembrolizumab plus chemotherapy versus chemotherapy were 88.2% versus 82.8% among patients with brain metastases and 94.5% versus 90.6% in those without. CONCLUSIONS: With or without brain metastasis, pembrolizumab plus platinum-based histology-specific chemotherapy improved clinical outcomes versus chemotherapy alone across all programmed death ligand 1 subgroups, including patients with programmed death ligand 1 tumor proportion score less than 1% and had a manageable safety profile in patients with advanced NSCLC. This regimen is a standard-of-care treatment option for treatment-naive patients with advanced NSCLC, including patients with stable brain metastases.
引用
- Powell SF, Rodríguez-Abreu D, Langer CJ, et al. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol. 2021. PMID: 34265431. doi:10.1016/j.jtho.2021.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。